In these cases, cancer proliferation depends on multiple oncogenes besides the oncogenic EGFR mutation, potentially resulting in a weaker oncogenic potential of EGFR and making EGFR-TKI monotherapy less effective as a front-line treatment. This evidence concerns the gene EGFR and cancer.